Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAILING: Dolutegravir vs Raltegravir in ART-Experienced HIV
NCT01231516Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2010
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of Participants With HIV-1 RNA <50 Copies/Milliliter at Week 48. Started Oct 2010; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01231516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01231516.